NCT07276620Not yet recruiting
Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults
A Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate to Severe Atopic Dermatitis in Adolescents and Adults
Source: ClinicalTrials.gov · Last updated 11 Dec 2025
Brief summary (registry, in English)
Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD. This study aims to evaluate the effectiveness and safety of Ivarmacitinib in the treatment of moderate-to-severe atopic dermatitis under real-world conditions. It will assess the time to pruritus improvement and skin lesion clearance, collect large-sample safety data, analyze disease improvement across patient subgroups with different baseline characteristics, and explore the impact of various maintenance treatment regimens on disease recurrence. It is expected that there will be no additional burden for participants in this trial.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 20 Nov 2025
- Start date
- 30 Nov 2025
- Primary completion date
- 30 Apr 2028
- Lead sponsor
- Xiangya Hospital of Central South University
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07276620
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 30 Nov 2025 to the primary completion date, 30 Apr 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject with a prior history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism, cerebrovascular accidents and those with known inherited conditions that predispose to hypercoagulability.
Other illness
- Subject has any malignancies or has a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.
- Presence of an active severe acute or chronic bacterial, fungal, or viral infection requiring systemic therapy.
- Subjects with active tuberculosis or known active hepatitis B and/or hepatitis C infection.
- Subjects with clinically significant diseases of the heart, liver, kidney, or other major organ systems.
Lab values
- Subject has any of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary:
- Absolute lymphocyte count of \<0.50 x 10\^9 /L (\<500/mm3);
- Absolute Neutrophil Count (ANC) of \<1 X 10\^9/L (\<1000/mm3);
- Hemoglobin level \< 80 g/L.
Other
- Female subject who is pregnant, breastfeeding, or considering pregnancy during the study.
Who the study is looking for
- Aged between 12 and 75 years;
- Diagnosed with moderate-to-severe atopic dermatitis (AD) ;
- Participants (and legal representatives for adolescents) able to understand and communicate with the investigator.
Age in the registry: 12 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.